Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer

Qian Zhang\(^a\), Yunen Liu\(^b\), Peng Chen\(^d\), Xiuyun Shi\(^b\), Ying Liu\(^b\), Lin Shi\(^b\), Peifang Cong\(^b\), Shun Mao\(^b\), Cangci Tong\(^b\), Cheng Du\(^c\), and Mingxiao Hou\(^{a,b}\)

\(^a\)College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, P.R. China; \(^b\)Emergency Medicine Department of General Hospital of Northern Theater Command, Laboratory of Rescue Center of Severe Wound and Trauma PLA, Shenyang, Liaoning, P.R. China; \(^c\)Department of Oncology, General Hospital of Northern Theater Command, Shenyang, Liaoning, P.R. China; \(^d\)Department of Urology, General Hospital of Northern Theater Command, Shenyang, Liaoning, P.R. China

**ABSTRACT**

The solute carrier family has been reported to play critical roles in the progression of several cancers; however, the relationship between solute carrier family 12 member 8 (SLC12A8) and bladder cancer (BC) has not been clearly confirmed. This study explores the prognostic value of SLC12A8 for BC and its correlation with immune cell infiltration. We found that the expression of SLC12A8 mRNA was significantly overexpressed in BC tissues compared with noncancerous tissues in multiple public databases, and the result was validated using real-time PCR and immunohistochemistry (IHC). The Kaplan-Meier method and Cox proportional hazards models were used to evaluate the prognostic value of SLC12A8 for BC. The high expression of SLC12A8 led to a shorter overall survival time and was an unfavorable prognostic biomarker for BC. The mechanisms of SLC12A8 promoting tumorigenesis were investigated by Gene Set Enrichment Analysis (GSEA). Moreover, the correlations of SLC12A8 expression with the tumor-infiltrating immune cells (TICs) in BC were explored using TIMER 2.0 and CIBERSORT. SLC12A8 was associated with CD4+ T cells, dendritic cells, neutrophils, and macrophages infiltration. The expression of SLC12A8 was positively correlated with crucial immune checkpoint molecules. In conclusion, SLC12A8 might be an unfavorable prognostic biomarker in BC related to tumor immune cell infiltration.

**Introduction**

The incidence of BC ranks 10th, and mortality ranks 13th in cancers globally; among men, BC ranks 7th in incidence and 9th in mortality [1–3]. Neoadjuvant or adjuvant chemotherapy improves survival and reduces the recurrence rate of muscle-invasive BC after radical cystectomy [4–6]. Nevertheless, 5-year survival from metastatic BC is only 5% [7]. Compared with traditional chemotherapy, immunotherapy has good efficacy in advanced or metastatic urothelial carcinoma [8]. Several immune checkpoint inhibitors (ICIs) have been approved as second-line treatments for patients that have progressed during or after previous platinum-based chemotherapy. Atezolizumab and pembrolizumab also received approval as first-line treatments for patients ineligible to receive cisplatin [9]. However, at present, immunotherapy still presents problems such as low response rates and high prices. Only a few patients can benefit from ICIs treatment. By contrast, many patients have an unsatisfactory response to ICIs, which may lead to economic waste. For these reasons, there is an urgent need to identify new predictors in cancer patients and select potential beneficiaries of immunotherapy to achieve precision therapy [10]. The outcomes and anti-tumor responses of immunotherapy depend on T cell infiltration [11]. In addition, TICs play a crucial role in tumor progression. Therefore, we investigated the abundance of immune cells in BC samples and correlated with the expression of SLC12A8.

SLC12A8 belongs to the solute carrier (SLC) transporters family. The most significant transporters in the body have essential roles in regulating the transport of substances inside and outside cells [12–16]. A recent study demonstrated that SLC12A8 is a nicotinamide mononucleotide transporter [17]. Although an association between the SLC family and the progression of urinary tract tumors has been mentioned, there is
a lack of sufficient evidence to establish a correlation between SLC12A8 and BC prognosis [18,19].

This study aimed to explore the prognostic value of SLC12A8 in BC using the public database TCGA and GES13507. To further confirm the clinical diagnostic value of SLC12A8, qPCR and immunohistochemistry (IHC) methods were performed in the collected clinical tissue samples. The possible molecular mechanisms and signal pathways by which SLC12A8 participates in BC were analyzed. Finally, Timer2.0 and CIBERSORT were used to evaluate the effect of SLC12A8 on immune cell infiltration and its relationship with immune checkpoint protein expression in BC.

Materials & methods

Databases

TCGA-BLCA includes gene profile data of 414 BC samples and 19 noncancerous samples. Oncomine and GES13507 were used to verify the differential expression of SLC12A8 mRNA in BC tissues (n = 188) and normal tissues (n = 68) [20,21]. Clinical and pathological data of BC patients were obtained from a TCGA-BLCA cohort (n = 427) and the GSE13507 cohort (n = 165). Patients with incomplete clinical information were excluded.

Evaluation of the prognostic value of SLC12A8 in BC

To further evaluate the prognostic value of SLC12A8 in BC, patients were divided into two groups according to the median expression of SLC12A8. The Kaplan-Meier method was used to explore 5-years overall survival or cancer-specific cancer specific survival time in TCGA and GSE13507. Univariate and multivariate Cox regressions were used to evaluate proportional hazards for overall survival [22]. The patients' risk scores were further evaluated, and the risk receiver operating characteristic (ROC) curves were plotted.

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis

Genes that are co-expressed with SLC12A8 were obtained from the Multi Experiment Matrix (MEM) (https://biit.cs.ut.ee/mem/index.cgi), a gene expression query, and visualization tool [23]. To explore the possible mechanism of SLC12A8 involvement in BC, co-expressed genes were used to conduct GO and KEGG genes to conduct GO and KEGG pathway analysis [24,25]. A protein-protein interaction (PPI) network analysis of SLC12A8 was conducted using STRING (https://string-db.org/) [26].

Gene Set Enrichment Analysis

GSEA v3.0 (http://www.broad.mit.edu/gsea/) was used to determine significant and concordant differences between a set of biological processes or signaling pathway genes from the Molecular Signatures Database (MsigDB) and SLC12A8 high expression groups based on TCGA with the cut-off criteria of FDR < 0.25 and nominal p < 0.05 [27].

Patients and characteristics

The study included 29 pairs of BC tissues and normal adjacent tissues from the General Hospital of Northern Theater Command between November 2019 and June 2020. Patient age ranged from 48 to 84 years, with a mean of 69.6 years, including 27 males and two females. All patients underwent radical cystectomy in the Department of Urology without chemotherapy. The tissues and paraffin sections used in this study were the remaining tissues and paraffin sections reserved in the pathology department. The General Hospital approved the study of Northern Theater Command (Shenyang, Liaoing, P.R. China), and all patients gave verbal consent. RB approval number: Y (2021) 039.

Cell culture

One normal human urinary tract epithelial SV-HUC-1 and five urinary BC cell lines (T24, UMUC3,5637, J82, and EJ-1) were obtained from FuHeng Biology. T24, 5637, and EJ-1 cells were cultured in RPMI 1640 medium, UMUC3 was cultured in DMEM medium, J82 was cultured in MEM medium, and SV-HUC-1 was cultured in F-12 K medium. All media contained 10% fetal bovine serum. The cell culture conditions were 37 °C and 5% CO2.
Real-Time PCR

Total mRNA of BC tissues or cell lines were extracted using TRIzol (Invitrogen, #119,706). Reverse transcription was performed using Fastking gDNA Dispelling RT SuperMix Kit (TIANGEN BIOTECH, #KR118). The reverse transcription conditions were as follows: 42 °C for 15 min, 95 °C for 3 min. qPCR was performed using the Thermo Scientific™ Real-Time PCR System (TIANLONG BIOTECHNOLOGY). According to SYBR Green Kit (BIO-RAD, #1,725,121), the reaction conditions were 95 °C for 60 sec, 95 °C for 10 sec, and 63 °C for 30 sec by 40 cycles. The sequence of SLC12A8 primer pairs were 5’- AGAACGATCCAGTGAGGC-3’ (forward), and 5’-CTGGGCTGGCTACTCGAG-3’ (reverse) and GAPDH were 5’-AGTCCACTGGCG TCTTCAC-3’ (forward) and 5’-GAGCGATT GCTGATGATCTTA-3’ (reverse). 2^ΔΔCT method was used to quantify relative SLC12A8 mRNA expression [28].

SLC12A8 IHC

The protein expression levels of SLC12A8 in tissue samples were determined using IHC. Briefly, 4-μm paraffin tissue chips were baked at 65 °C for 1 hour before dewaxing. The staining procedure was operated according to the IHC kit protocol (Maxim Biotechnology) using the SLC12A8 antibody (Biorbyt, #orb317876,1:200 dilution). The sections were subjected to DAB color development, hematoxylin staining, dehydration, and sealing. The sections were taken photographs under a microscope with ×100 and ×200 magnification. IHC profiler, a plug-in of Image J, was used to analyze the immunohistochemical results. The percentage of positive cells was divided into five grades according to the following scoring rules: less than 10% = 0, 10%–25% = 1, 26–50% = 2, 51–75% = 3 score, and more than 75% = 4. The staining intensity was divided into four grades: negative = 0, weak staining = 1, moderate staining = 2, and strong staining = 3. The positive proportion score was multiplied by the staining intensity score; according to the corresponding expression classification, 0–3 points indicated low expression and 4–12 points indicated high expression [29].

Evaluation of immune infiltration

The proportion of 22 immune cells in BC samples were calculated using CIBERSORT [30,31]. TIMER2.0 provides a more comprehensive assessment of immune infiltration levels using seven state-of-the-art algorithms for TCGA [32]. It provides correlations between gene expression and the level of 20 cell immune infiltrates in various cancer types. We summarized the correlation between SLC12A8 expression and immune cell infiltrates in BC using all algorithms including TIMER, CIBERSORT, CIBERSORT-ABS, EPIC, QUANTISEQ, XCELL, and MPC-COUNTER provided in TIMER2.0 and displayed them with a heatmap.

Correlation with immune checkpoints

To evaluate the response and therapeutic outcomes of immune checkpoints through SLC12A8 gene expression, we further analyzed the correlation between SLC12A8 expression and important immune checkpoints gene expression according to TCGA-BLCA expression profile data [33]. TIMER2.0 provided Pearson correlation coefficients between genes.

Statistical analysis

Statistical processing and analysis were performed using R (version 3.6.2) and SPSS Statistics 26.0 in this study. Independent T-tests or non-parametric tests were used to compare SLC12A8 mRNA expression between groups. The chi-squared test was to determine relevance between clinicopathologic characteristics and SLC12A8 expression levels [34]. The Kaplan–Meier method was used for survival analysis. A Cox analysis regression model was used to assess independent prognostic factors. ROC curves were used to estimate the diagnosis values.

Results

The expression of the SLC12A8 gene was significantly increased in BC tissues identified by bioinformatics analysis and experiment determination. Overexpression of SLC12A8 was correlated with poor outcome as an unfavorable biomarker in BC.
We also found that SLC12A8 was related to immune cell infiltration and positively correlated with crucial immune checkpoint molecules in BC. The pathway analysis indicated the mechanism of SLC12A8 involved in the tumorigenesis.

**Overexpression of SLC12A8 mRNA in BC**

The expression levels of SLC12A8 mRNA in normal and BC tissues were evaluated using BC gene expression profiles from TCGA-BLCA. The expression of SLC12A8 mRNA was significantly greater in BC tissues than in normal tissues (p < 0.001 Figure 1a). A greater expression of SLC12A8 mRNA in BC tissues than normal tissues was validated using the GSE13507 dataset (Figure 1b). The Oncomine database indicated that SLC12A8 mRNA levels were elevated in infiltrating urothelial bladder tissues than those in normal tissues from two datasets (Figure 1c, 1d). qPCR analysis of 25 groups of clinical tissues confirmed that the expression levels of SLC12A8 in tumor tissues were significantly greater (Figure 1e). However, qPCR in the cell lines showed that, compared with normal bladder epithelial cells (SV-HUC-1), expression levels of SLC12A8 mRNA in J82 and 5637 were greater, T24, EJ-1, and UMUC3 were lower (figure 1f).

**Kaplan-Meier survival analysis of SLC12A8 in BC**

To evaluate the prognostic value of SLC12A8 in BC, the survival data of patients in TCGA and GSE13507 were analyzed. BC patients with high expression of SLC12A8 had remarkably shorter overall survival than those in the low expression group both in TCGA (p = 0.014, Figure 2a) and GES13507 cohort (p = 0.0081, Figure 2b). Consistently, SLC12A8 overexpression was considered a prognostic factor of cancer-specific survival in GSE13507. (p = 0.007, Figure 2c).

**Correlation between SLC12A8 mRNA expression and the clinical characteristics of BC patients**

Clinical characteristics of 427 BC patients from TCGA-BLCA cohort and 165 patients from the GSE13507 cohort were associated with high and low SLC12A8 expression. SLC12A8 mRNA expression was significantly associated with age (p < 0.01), pathological stage (p < 0.001), histological grade (p < 0.001), N stage (p < 0.001) and M stage (p < 0.001) in TCGA-BLCA cohort. In the GSE13507 dataset, the expression of SLC12A8 was closely associated with age (p < 0.001), pathological grade (p < 0.001), T stage (p < 0.001), and N stage (p < 0.05) (Table 1).

**Cox univariable and multivariable analysis of overall survival among BC patients**

In TCGA-BLCA cohort, Cox univariable analysis showed pathological stage (hazard ratio (HR) = 1.7618, p < 0.001), T stage (HR = 1.6423, p < 0.001), N stage (HR = 1.5524, p < 0.001), M stage (HR = 2.4975, p < 0.01) and SLC12A8 expression (HR = 1.5810, p < 0.001) influenced overall survival. Multivariable Cox analysis showed that only SLC12A8 expression (HR = 1.4185, p < 0.001) independently influenced overall survival among BC patients (Table 2). In the GSE13507 cohort based on univariate Cox analysis, SLC12A8 overexpression was predicted poor cancer-specific survival in BC patients (HR = 1.2338, p < 0.01); however, it was not an independent factor by multivariable Cox analysis (HR = 0.6537, p = 0.2715) (Table 3). To determine the diagnostic capacity of SLC12A8 expression as an unfavorable prognostic biomarker in BC, we calculated the area under the curve (AUC) values of 5-year survival risks using ROC curves. The AUCs were 0.681 and 0.857 for the TCGA and GSE13507 cohorts, respectively (Figure 3a, 3b).

**IHC of SLC12A8 protein expression**

IHC was performed on 29 paired BC tissues and adjacent normal tissues to examine SLC12A8 protein expression levels further. Representative IHC staining image indicated that SLC12A8 was located in the cytoplasmic and plasma membrane. IHC scores suggested that levels of protein expression of SLC12A8 in BC tissues were significantly higher than in adjacent tissues (Figure 4a, 4b). According to the pathological grade, the IHC staining of the low-grade group was negative (Figure 4c). In contrast, the staining of patients diagnosed as high-grade were weak (Figure 4d), moderate (Figure 4e), or strong (figure 4f). IHC staining scores of SLC12A8 in the BC group were significantly higher than in the normal group (P < 0.005) (Figure 4g).
The genes co-expressed with SLC12A8 were found in MEM and cBioPortal databases. There were 50 co-expressed genes of SLC12A8 in the MEM (P < 0.001) and cBioPortal databases. Spearman correlation coefficient > 0.4 was used as the criteria for inclusion (P < 0.001). The GO and KEGG analyses of 483 co-expressed genes.
after eliminating duplicates showed that they were enriched in extracellular matrix tissue, cell adhesion, inflammatory response, and signal transduction in terms of biological process (Figure 5a). The co-expressed genes were enriched in the collagen-containing extracellular matrix, endoplasmic reticulum cavity, focal adhesion, and cell-substrate adhesion (Figure 5b). The co-expressed genes were enriched in extracellular matrix structural constituents, glycosaminoglycan binding, and immunoglobulin binding (Figure 5c). The KEGG pathway indicated that co-expressed genes were enriched in the PI3K-Akt signaling pathway, extracellular matrix (ECM)-receptor interactions, proteoglycans in cancer, cytokine-cytokine receptor interactions, cell adhesion molecules, the toll-like receptor signaling pathway, the NF-kappa B signaling pathway, and focal adhesion (Figure 5d).

The PPI network of SLC12A8 described by STRING to detect the interacting protein showed 11 nodes, 15 edges, and an average local clustering coefficient of 0.919 (Figure 6). Cystatin A, the maximum-score protein, mediates cell-cell adhesion in the lower levels of the epidermis. SLC22A2-mediated tubular uptake of organic compounds from circulation and ESYT3-associated lipid transport in cellular were proteins co-expressed with SLC12A8.

**SLC12A8 associated gene set enrichment in cancer**

We used GSEA to identify associated genes enriched in response to SLC12A8 high expression based on TCGA-BLCA. The chemokine signaling
### Table 1. Association between clinical characteristics of BC patients and SLC12A8 expression.

| clinical characters | TCGA cohort | | GSE13507 cohort | |
|---------------------|-------------|-----------------|-----------------|-----------------|
|                      | SLC12A8 Low expression | SLC12A8 High expression | P | SLC12A8 Low expression | SLC12A8 High expression | P |
|                      | (n = 213) | (n = 214) | | (n = 82) | (n = 83) | |
| Age                 | 0.006 | | | 0.026 | |
| <65                 | 91(42.7%) | 64(29.9%) | | 36(43.90%) | 23 (27.71%) | |
| ≥65                 | 122(57.3) | 150(70.1%) | | 46(56.10%) | 60 (72.29%) | |
| Gender              | 0.534 | | | 0.442 | |
| MALE                | 158(74.2%) | 153(71.5%) | | 69(84.15%) | 66(79.52%) | |
| FEMALE              | 55(25.8%) | 61(28.5%) | | 13(15.85%) | 17(20.48%) | |
| Pathological stage  | <0.001 | | | | |
| Stage I&II          | 92(43.2%) | 44(20.56%) | | NA | NA | |
| Stage III&IV        | 120(56.3%) | 169(78.97%) | | NA | NA | |
| No data             | 1(0.47%) | 1(=0.47%) | | NA | NA | |
| Histological grade  | <0.001 | | | <0.001 | |
| Low grade           | 21(9.86%) | 0(0.00%) | | 69(84.15%) | 36(43.37%) | |
| High grade          | 192(90.14%) | 211(98.60%) | | 13(15.85%) | 47(56.63%) | |
| No data             | 0(0.00%) | 3(1.40%) | | | | |
| T stage             | 0.967 | | | <0.001 | |
| T1                  | 20(9.94%) | 20(9.93%) | | 19(23.17%) | 41(49.40%) | |
| T2                  | 191(89.67%) | 199(93.00%) | | 63(76.83%) | 42(50.60%) | |
| No data             | 20(9.39%) | 13(6.07%) | | 19(23.17%) | 41(49.40%) | |
| N stage             | <0.001 | | | 0.008 | |
| N0                  | 141(66.20%) | 107(50.00%) | | 79(96.34%) | 68(81.93%) | |
| N1                  | 53(24.88%) | 84(39.25%) | | 3(3.66%) | 13(15.66%) | |
| No data             | 19(8.92%) | 23(10.75%) | | 79(96.34%) | 68(81.93%) | |
| M stage             | 0.044 | | | 0.45 | |
| M0                  | 153(71.83%) | 53(24.77%) | | 80(97.56%) | 78(93.98%) | |
| M1                  | 4(1.88%) | 6(2.80%) | | 2(2.44%) | 5(6.02%) | |
| No data             | 56(26.29%) | 155(72.43%) | | | | |

### Table 2. Univariate and multivariate cox analysis of clinical characteristics for OS in TCGA cohort.

| Clinical Variables | TCGA cohort | | TCGA cohort | |
|--------------------|-------------|-----------------|-----------------|-----------------|
|                    | Univariate analysis | | Multivariate analysis | |
|                    | HR | HR.95L | HR.95H | P value | HR | HR.95L | HR.95H | P value |
| Gender              | 0.6457 | 0.3857 | 1.0808 | 0.096 | 0.6862 | 0.4013 | 1.1734 | 0.1689 |
| Age                | 1.0245 | 0.999 | 1.0505 | 0.0596 | 1.0201 | 0.9936 | 1.0472 | 0.1379 |
| Grade              | 3.7586 | 0.5167 | 27.3424 | 0.191 | 1.1678 | 0.1464 | 9.3138 | 0.8836 |
| Stage              | 1.7618 | 1.2643 | 2.455 | 0.0008 | 1.0986 | 0.5417 | 2.2282 | 0.7944 |
| M                  | 2.4975 | 0.9971 | 6.2556 | 0.0507 | 1.3638 | 0.4632 | 4.0152 | 0.5733 |
| N                  | 1.5524 | 1.2057 | 1.9986 | 0.0006 | 1.2343 | 0.7487 | 2.0347 | 0.4091 |
| T                 | 1.6423 | 1.1447 | 2.3562 | 0.0071 | 1.3639 | 0.8317 | 2.2366 | 0.2189 |
| SLC12A8            | 1.581 | 1.209 | 2.0675 | 0.0008 | 1.4185 | 1.0395 | 1.9355 | 0.0275 |

### Table 3. Univariate and multivariate cox analysis of clinical characteristics for cancer specific survival in GSE13507 cohort.

| Clinical Variables | GSE 13507 cohort | | GSE 13507 cohort | |
|--------------------|-----------------|-----------------|-----------------|-----------------|
|                    | Univariate analysis | | Multivariate analysis | |
|                    | HR | HR.95L | HR.95H | P value | HR | HR.95L | HR.95H | P value |
| Gender              | 0.4561 | 0.2097 | 0.9922 | 0.0477 | 0.6453 | 0.2686 | 1.5506 | 0.3275 |
| Age                | 1.0526 | 1.0166 | 1.0899 | 0.0039 | 1.0924 | 1.0402 | 1.1473 | 0.0004 |
| Grade              | 5.7791 | 2.6494 | 12.6058 | 0.0000 | 0.8197 | 0.3186 | 2.1091 | 0.6801 |
| M                  | 13.8632 | 5.552 | 34.616 | 0.0000 | 8.5178 | 2.32 | 31.2731 | 0.0012 |
| N                  | 10.328 | 4.9256 | 21.6557 | 0.0000 | 2.2339 | 0.8627 | 5.7845 | 0.0978 |
| T                  | 3.7044 | 2.6058 | 5.2663 | 0.0000 | 1.9891 | 1.1159 | 3.5454 | 0.0197 |
| Invasiveness       | 24.1573 | 7.3165 | 79.7621 | 0.0000 | 4.9689 | 0.8543 | 28.901 | 0.0743 |
| Progressive        | 6.1295 | 3.0161 | 12.4569 | 0.0000 | 6.416 | 2.4492 | 16.8071 | 0.0002 |
| SLC12A8            | 2.0518 | 1.2338 | 3.412 | 0.0056 | 0.6537 | 0.3064 | 1.3946 | 0.2715 |
pathway, cell adhesion molecules, ECM receptors, and the cancer pathway related to tumorigenesis, invasion, and metastasis were significantly enriched in the group of high SLC12A8 expression. GSEA analysis indicated that SLC12A8 might play an essential role in BC development (Figure 7).

**Correlation between SLC12A8 and TICs**

The compositions of 22 immune cells in BC samples calculated by CIBERSORT were filtered using the criterion P < 0.05, and the filtered results of 11 normal samples and 238 tumor samples were displayed using a barplot (Figure 8a). The seven algorithms possess varying accuracies for estimating different cell types; Timer 2.0 summarizes the results of these important algorithms. This study extracted the correlation between the SLC12A8 gene and TICs in patients with BC and drew the heat map (Figure 8b). According to the results of the CIBERSORT method, SLC12A8 expression was positively correlated with CD4+ memory activated T cells, neutrophil, M0, M1, M2 macrophage, and gamma delta T cells, and negatively correlated with resting CD4+ memory T cells, activated dendritic cells, and follicular helper T cells (Figure 8c).

**SLC12A8 was positively correlated with common immune checkpoints**

The effect of gene expression level on the potential efficacy of immunotherapy was further investigated. We found that the expression of SLC12A8 was positively correlated with the expression of immunotherapy-related markers, PDL-1 (p < 0.001), CTLA-4 (p < 0.001), LAG-3 (p < 0.001), TIM-3 (p < 0.001) and TIGIT (p < 0.001), stimulatory checkpoint molecules, GITR (p < 0.001), ICOS (p < 0.001) and CD27 (p < 0.001) (Figure 9a). Spearman’s correlation analysis of SLC12A8 gene expression and major immune checkpoints were conducted using TIMER 2.0. SLC12A8 expression showed a positive correlation with major immune checkpoint molecules PD-L1 (PDCD1), LAG3, TIM-3 (Havcr2), CTLA-4, and TIGIT (Figure 9b).

**Discussion**

Due to the lack of confirmed specific molecules, BC diagnosis and targeted therapy are
greatly restricted [35]. Therefore, new therapeutic strategies and biomarkers are needed urgently. The SLC family is relevant to the genesis and progression of various cancers [36–38]. SLC transporters for essential nutrients may promote tumor occurrence; however, some subtypes inhibit tumors by increasing the accumulation of anti-tumor drugs in cells [39]. Also, SLC transporters can mediate immune cell homeostasis through transporters of immune cells [40,41].

Furthermore, SLC transporters regulate energy metabolism by glucose uptake mediation and then affect cell proliferation and tumor microenvironment [42,43]. SLC12A8 is a member of the SLC family that
**Figure 5.** GO and KEGG analysis of co-expression genes of SLC12A8. (a) GO analysis for biological process. (b) GO analysis for cellular components. (c) GO analysis for molecular functions. (d) KEGG pathway analysis.

**Figure 6.** The PPI networks of SLC12A8 protein performed by STRING.
participates in various biological processes, including ion and nutrient delivery, cell energy metabolism and cell volume regulation, and drug delivery [44]. Whether the relationship between SLC12A8 and tumor is related to the mechanism of immunity, signal transduction, and tumor microenvironment has not been clarified.

In the present research, we used public cancer databases for data mining and found SLC12A8 mRNA overexpression in BC associated with poor prognosis. Real-time PCR further validated the finding in BC tissues and urinary tract cell lines. SLC12A8 mRNA expression was significantly elevated in BC tissues. However, the fold change of SLC12A8 mRNA in T24, UMUC3, and EJ-1 was negative, consistent with published data in Broad Institute Cancer Cell Line Encyclopedia (https://portals.broadinstitute.org/ccle). The expression of SLC12A8 protein was localized to the cell membrane. The staining of normal and low-grade tissues was almost negative, and the high-grade presented weak, moderate, or intense staining.

To further explore the possible mechanism of SLC12A8 in the progression of BC, we performed GO, KEGG, and PPI analyses. GO & KEGG pathway analysis and GSEA results revealed that SLC12A8 mainly affects tumor progression by acting on tumor-related pathways, including NF-kb, PI3K-Akt, and Toll-like receptors. Meanwhile, SLC12A8 may regulate ECM-receptor interaction, extracellular matrix organization, cell adhesion, and immunoglobulin binding to impact tumor microenvironment and immunity. Cystatin A, a protein that interacts with SLC12A8, is a putative tumor suppressor that modulates extracellular matrix remodeling, cell adhesion, tumor invasion, and metastasis [45,46]. By contrast, in some studies, cystatin A was considered a poor prognostic biomarker in pancreatic cancer, nasopharyngeal carcinoma, and non-small-cell lung cancer [47–49].

The tumor microenvironment plays an integral part in various processes of tumorigenesis as well as immune responses [50]. In recent years, the use of ICIs has made irreplaceable achievements in the treatment of BC. Atezolizumab and pembrolizumab targeting PD-1 have been approved as first-line treatment for cisplatin-ineligible metastatic urothelial BC by the Food and Drug Administration [51–54]. ‘Cold’ tumor with low T cell infiltration is a critical reason for the resistance to immunotherapy [55,56]. It is essential to determine tumor immune cell infiltration to understand
tumor progression and improve the response to immunotherapy. However, no studies have been conducted on the effect of SLC12A8 on the tumor microenvironment. We used CIBERSORT and TIMER 2.0 to analyze the tumor immune cell infiltration of SLC12A8 in bladder cancer. Limitations of various methods to estimate the immune cell composition led to a difference in results. According to CIBERSORT, SLC12A8 may be involved in the complex tumor microenvironment by regulating CD4+ T memory cells, DC cells, macrophages (M0, M1, M2), neutrophils, γδ T cells, and follicular T-helper cells.

Figure 8. The abundance of immune cells in BC samples and TICs correlation with SLC12A8 expression. (a) Barplot showing the proportion of 22 immune cells in BC samples. (b) Heatmap showing the Spearman’s coefficient of TICs and SLC12A8 expression through seven different algorithms. (c) Scatter plot showing the correlation of nine TICs with SLC12A8 expression in CIBERSORT (p < 0.05).
In addition, we found that the expression of SLC12A8 was significantly positively correlated with the expression of common immune checkpoint biomarkers, suggesting that SLC12A8 may inhibit the immune response by inducing the expression of immune checkpoint molecules. Some studies confirmed that high expression of immune checkpoint molecules is associated with a higher response rate. We speculate that the expression of SLC12A8 may potentially predict the response of immune checkpoint therapy for BC.

In summary, we proposed a prognostic model of SLC12A8 expression level and survival rate in

Figure 9. The correlation of SLC12A8 expression with immune checkpoints. (a) The expression of immunotherapy-related markers was evaluated in SLC12A8 high expression groups. (b) Spearman’s coefficient of immune checkpoints and SLC12A8 expression analyzed using TIMER2.0.
patients with BC. We confirmed overexpression in BC tissues in many databases, clinical samples, and cell lines. More importantly, we first used IHC to analyze SLC12A8 protein expression in normal tissues and bladder tumors, providing evidence for SLC12A8 as a potential diagnostic marker for BC. Furthermore, we found that SLC12A8 may affect the tumor microenvironment and may be a potential marker of immunotherapy response. However, there are some limitations to our study. Our sample size was insufficient and lacked overall survival information. The molecular mechanism of SLC12A8 and research on how it activates the signaling pathway for BC development will be further explored. In addition, we will further investigate the value of SLC12A8 in immunology, such as the effect of SLC12A8 gene expression on immune checkpoint inhibitor response.

Conclusion

This study confirmed that SLC12A8 was significantly overexpressed in clinical BC tissues using bioinformatics, real-time PCR, and IHC methods. The high expression of SLC12A8 is related to poor outcomes in BC. Subsequently, we found that SLC12A8 was associated with multiple tumor immune cell infiltration and positively correlated with immune checkpoint molecules in BC. SLC12A8 may be a potential biomarker and immunotherapy-related target.

Acknowledgements

We thank the Laboratory of Rescue Center of Severe Wound and Trauma PLA and the Department of Oncology of General Hospital of Theater Command for providing the research platform for this study.

Highlights

1. Bioinformatics analysis and clinical tissue validation were combined to analyze the gene expression of SLC12A8 in BC comprehensively.
2. The correlation between SLC12A8 and tumor immune cell infiltration was explored.
3. The prognostic value of SLC12A8 was evaluated, and its correlation with immune checkpoints was analyzed.

Abbreviations

- Solute carrier family 12 member 8 (SLC12A8)
- Bladder cancer (BC)
- Gene Set Enrichment Analysis (GSEA)
- Tumor-infiltrating immune cells (TICs)
- Multi Experiment Matrix (MEM)
- Programmed cell death protein 1 (PD-1)
- Programmed death-ligand 1 (PD-L1)
- Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
- Lymphocyte activation gene 3 protein (LAG3)
- T cells immunoglobulin domain mucin domain protein-3 (TIM3)
- T cell immunoglobulin and ITIM domain protein (TIGIT)
- Molecular Signatures Database (MsigDB)
- Gene Ontology (GO)
- Kyoto Encyclopedia of Genes and Genomes (KEGG) Area under the curve (AUC)/Hazard ratio (HR)
- Receiver operating characteristic (ROC)
- Extracellular matrix (ECM)
- Immune checkpoint inhibitors (ICIs)

Ethics approval and consent to participate

The ethics committee approved the study of the General Hospital of Northern Theater Command (Shenyang, Liaoning, P.R. China), and the IRB approval number is Y (2021) 039.

Consent for publication

All the authors agree to publish in this journal.

Disclosure statement

We declare that we have no competing interests and personal relationships with other people or organizations.

Funding

This work was supported by the Liaoning Provincial Natural Science Foundation (the clinical and translational research of cold plasma combined with targeted SLC12A8 for local therapy of BC, 2020-MS-039, Cheng Du).

Author’s contributions

Qian Zhang, Cheng Du, Yunen Liu conceived and designed the experiments. Qian Zhang, Xiuyun Shi, and Ying Liu performed the experiments. Qian Zhang, Lin Shi, and Peng Chen processed the data. Peifang Cong, Shun Mao, and Cangci Tong prepared the figures and tables Qian Zhang drafted the work. Mingxiao Hou revised it critically for important content.
Availability of data and materials

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

References

[1] ANTONI S, FERLAY J, SOERjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends [J]. European Urology. 2017;71(1):96–108.

[2] SAGINALA K, BARSOUK A, ALURU J, et al. Epidemiology of bladder cancer [J]. John Wiley & Sons, Inc. 2020;5(4):1.

[3] SIEGEL R, MILLER K, JEMAL A. J C A C J C F C. Cancer Stat. 2020;70(1):7–30. 2020 [J].

[4] DEL BENE G, CALABRò F, GIANNARELLI D, et al. Neoadjuvant vs. adjuvant chemotherapy in muscle invasive bladder cancer (MIBC): Analysis from the RISC database [J]. Front Oncol. 2018;8:463.

[5] Keck B, WACH S, Taubert H, et al. Neuprolip-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients [J]. International Journal of Cancer. 2015;136(2):443–451.

[6] Sanford T, MENG M, RAILKAR R, et al. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma [J]. Clinical Epigenetics. 2018;10(1):19.

[7] Lei A, CHENG L, Pan C. JEROAT. Current treatment of metastatic bladder cancer and future directions [J]. Expert Review of Anticancer Therapy. 2011;11(12):1851–1862.

[8] GRIVAS P, AGARWAL N, Pal S, et al. Avellumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice [J]. Cancer Treatment Reviews. 2021;97:102187.

[9] Aurilio G, CIMADAMORE A, LOPEZ-BELTRAN A, et al. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer [J]. Translational Andrology and Urology. 2021;10(3):1521–1529.

[10] Li X, LUO L, JIANG M, et al. Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function [J]. Journal of Controlled Release. 2021;334:413–426.

[11] LIU Y. SUN Z J T. Turning cold tumors into hot tumors by improving T-cell infiltration [J]. Theranostics. 2021;11(11):5365–5386.

[12] BAI X, MORAES T, REITHMEIER R J M M B. Structural biology of solute carrier (SLC) membrane transport proteins [J]. Mol Membr Biol.2017;34;1–32.

[13] GARIBSINGH R, SCHLESSINGER A J T I P S. advances and challenges in rational drug design for SLCs [J]. Trends Pharmacol Sci. 2019;40(10):790–800.

[14] Li Q, SHU YJM, Therapies C. Role of solute carriers in response to anticancer drugs [J]. Molecular & Cellular Therapies. 2014;2(1):15.

[15] Saito Y, Li L, Coyaud E, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER breast cancer [J]. Nature. 2019;569(7755):275–279.

[16] Shen L, Qian C, CAO H, et al. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma [J]. World J Surg Oncol. 2018;16(1):235.

[17] GROZIO A, Mills K, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter [J]. Nat Metab. 2019;1(1):47–57.

[18] Fangning W, Chenguang M, Hailiang Z, et al. Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma [J]. J Cancer. 2017;8(11):2010–2017.

[19] Wang L, Zhang Q, Wu P, et al. SLC12A5 interacts and enhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7 [J]. Cancer Sci. 2020;111(7):2349–2360.

[20] Zhang L, Li L, Zhan Y, et al. Identification of immune-related lncRNA signature to predict prognosis and immunotherapeutic efficiency in bladder cancer [J]. Front Oncol. 2020;10:542140.

[21] HU J, ZHOU L, Song Z, et al. The identification of new biomarkers for bladder cancer: a study based on TCGA and GEO datasets [J]. Journal of Cellular Physiology. 2019;234(9):15607–15618.

[22] Chen S, Zhang N, Shao J, et al. A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer [J]. Journal of Cancer. 2019;10(23):5744–5753.

[23] Chen M, Zhang S, Wen X, et al. Prognostic value of Clinc3 mRNA overexpression in bladder cancer [J]. PeerJ. 2020;8:e8348.

[24] Xu Y, Wu G, Li J, et al. Screening and identification of key biomarkers for bladder cancer: a study based on TCGA and GEO data [J]. BioMed Research International. 2020;2020:1–20.

[25] Xu H, Xiong C, Chen Y, et al. Identification of rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma [J]. Bioengineered. 2021;12(1):2664–2675.

[26] Sang L, Sun L, Wang A, et al. The N6-methyladenosine features of mRNA and aberrant expression of m6A modified genes in gastric cancer and their potential impact on the risk and prognosis [J]. Front Genet. 2020;11:561566.

[27] Liu S, He L, Sheng C, et al. Overexpression of RIPK4 predicts poor prognosis and promotes metastasis in ovarian cancer [J]. BioMed Research International. 2021;2021(6):1–11.

[28] Arab A, Karimipoor M, Irani S, et al. Potential circulating miRNA signature for early detection of NSCLC [J]. Cancer Genetics. 2017:150–158.
[29] Song Y, Huang R, Wu S, et al. Diagnostic and prognostic role of NR3C4 in breast cancer through a genomic network understanding [J]. Pathol Res Pract. 2021;217:153310.

[30] LIU Y, Wu Y, ZHANG P, et al. CXCL12 and CD3E as Indicators for tumor microenvironment modulation in bladder cancer and their correlations with immune infiltration and molecular subtypes [J]. Front Oncol. 2021;11:636870.

[31] XUE G, HUA L, ZHOU N, et al. Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis [J]. Bioengineered. 2021;12(1):252–265.

[32] Li T, FU J, ZENG Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells [J]. Nucleic Acids Res. 2020;48:W509–W14.

[33] Xu F, SHEN J, Xu SJIC, et al. Integrated bioinformatical analysis identifies GIMAP4 as an immune-related prognostic biomarker associated with remodeling in cervical cancer tumor microenvironment [J]. Frontiers in Cell and Developmental Biology. 2021; 9:637400.

[34] Wang L, Wang P, SU X, et al. Circ_0001658 promotes the proliferation and metastasis of osteosarcoma cells via regulating miR-382-5p/YB-1 axis [J]. Cell Biochemistry and Function. 2020;38(1):77–86.

[35] DEVELOPMENT, SMOLENSKY D, RATHORE K, CEKANOVA MJDD, et al. Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer [J]. Drug Design Development & Therapy. 2016;10:3305–3322.

[36] Wang L, LEITE DE OLIVEIRA R, HUJIBERTS S, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential [J]. Cell. 2018;173:1413–1425.e14.

[37] Sprowl J, MIKKELEN T, GIOVINAZZO H, et al. Contribution of tumor and host solute carriers to clinical drug response [J]. Drug Resist Updat. 2012;15(1-2):5-20.

[38] Cervenková L, VYCITÁL O, BRUHA J, et al. Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma [J]. Sci Rep.2019;9:19782.

[39] Sutherland R, MEESON A. LOWES S J C M R. Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis [J]. Cancer Metastasis Rev. 2020;39(3):919–932.

[40] ANSARI R, Craze M, Althobiti M, et al. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer [J]. Br J Cancer. 2020;122(1):94–101.

[41] Song W, Li D, Tao L, et al. Solute carrier transporters: the metabolic gatekeepers of immune cells [J]. Acta Pharmaceutica Sinica B. 2020;10(1):61–78.

[42] MORIKA S, Perry J, Raymond M, et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release [J]. Nature. 2018;563:714–718.

[43] ZHANG Y, ZHANG Y, Sun K, et al. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development [J]. J Mol Cell Biol. 2019;11(1):1–13.

[44] Lin L, YEE S, Kim R, et al. SLC transporters as therapeutic targets: emerging opportunities [J]. Nature Reviews Drug Discovery. 2015;14(8):543–560.

[45] Ma Y, Chen Y, Li Y, et al. Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer [J]. Oncotarget. 2018;9(18):14084–14098.

[46] John Mary D, SIKARWAR G, KUMAR A, et al. Interplay of ERa binding and DNA methylation in the intron-2 determines the expression and estrogen regulation of cystatin A in breast cancer cells [J]. Molecular and Cellular Endocrinology. 2020;504:110700.

[47] KOMURA T, TAKABATAKE H, HARADA K, et al. Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma [J]. Cancer Sci. 2017;108(11):2122–2129.

[48] Cai Y, Li J, Lu A, et al. Increased serum levels of macrophage inflammatory protein-3a and cystatin a predict a poor prognosis of nasopharyngeal carcinoma [J]. Medicine. 2014;93(22):e123.

[49] Butler M, FUKUI T, SALIT J, et al. Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer [J]. Cancer Research. 2011;71(7):2572–2581.

[50] AUGUSTIN R, DELGOFFE G, NAJJAR YJC. Characteristics of the tumor microenvironment that influence immune cell functions: Hypoxia, oxidative stress, metabolic alterations [J]. Cancers. 12(12):2020.

[51] Lyu Q, Lin A, CAO M, et al. Alterations in TP53 are a potential biomarker of bladder cancer patients who benefit from immune checkpoint inhibition [J]. Cancer control: journal of the Moffitt Cancer Center. 2020;27(1):1073274820976665.

[52] LOPEZ-BELTRAN A, CIMADAMORE A, Blanca A, et al. Immune checkpoint inhibitors for the treatment of bladder cancer [J].Cancers. 2021; 13(1).

[53] SZABADOS B, PRENDERGAST A, Jackson-spence F, et al. Immune checkpoint inhibitors in front-line therapy for urothelial cancer [J]. Eur Urol Oncol. 2021;30: S2588-9311(21)00044-4.

[54] YANG H, Wu C, Chen J, et al. Treatment strategies and metabolic pathway regulation in urothelial cell carcinoma: a comprehensive review [J].Int J Mol Sci. 2020;21(25):8993.

[55] NISAR S, YOUSUF P, MASOODI T, et al. Chemokine-cytokine networks in the head and neck tumor microenvironment [J]. International Journal of Molecular Sciences. 2021;22(9)(4584):1–23.

[56] STURM G, FINOTELLO F, PETITPREZ F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno- oncology [J]. Bioinformatics.2019;35(14):i436–i445.